Inclisiran

Grey

Brand Name(s):Leqvio

Indication:Adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia

Rationale:2

Considered:Feb-21

Review Date:Feb-26

Comments:
Inclisiran is licensed for the treatment of adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet, either alone or in combination with a statin or statin with other lipid-lowering therapies.

The recommended dose is 284 mg inclisiran administered as a single subcutaneous injection: initially, again at 3 months, followed by every 6 months.

Missed doses – If a planned dose is missed by more than 3 months, a new dosing schedule should be started – inclisiran should be administered initially, again at 3 months, followed by every 6 months.